

## ASX RELEASE

### **Volpara to collaborate with leading genetics company Natera**

Wellington, NZ, 30 September 2021: Volpara Health Technologies Limited ("Volpara," "the Group," or "the Company"; ASX:VHT), a global health technology software leader providing an integrated platform for the delivery of personalised breast care, has entered into a collaboration agreement with Natera, Inc. ("Natera"), a NASDAQ-listed global leader in cell-free DNA testing with a market cap in excess of US\$10Bn, to bring Natera's Empower Hereditary Cancer Test to Volpara's customers in the United States.

#### **Highlights:**

- **Volpara's US customers will get access to Natera's comprehensive genetic testing services within Volpara's software workflow**
- **Volpara plans to create a fully integrated ordering process for Natera genetic testing services within the Volpara® Breast Health Platform™**
- **As part of the agreement, Volpara has the potential to offer increased value to mutual customers upon successful clinical implementation**

Volpara will integrate Natera's Empower Hereditary Cancer Test into Volpara's software workflow to create additional access for women to comprehensive genetic testing services in different clinical settings. At least one Volpara software product is used with over 33% of women who attend screening each year in the United States. Customers use Volpara's market-leading breast cancer risk assessment software to confidently make informed decisions for triaging patients to supplemental imaging and/or genetic testing based on their personalised risk.

Risk assessment is also required by many US insurance companies before additional testing. Along with supplemental screening, such as ultrasound and MRI, genetic testing assists in earlier cancer detection and is critical in reducing treatment costs and increasing the chances of survival.

Dr. Ralph Highnam, Group CEO of Volpara, said: "By adding Natera to our Breast Health Platform, we continue to build our integrations with best-of-breed genetic testing companies in order to offer our customers greater options. Natera will allow us to continue driving the adoption of personalised breast screening in the United States. We continue to see strong

interest in our risk offerings and the ability to direct women to the appropriate genetic testing at the right time.”

### **Authorisation & Additional Information**

This announcement was authorised by the Group CEO Dr Ralph Highnam.

### **ENDS**

### **For further information, please contact:**

Ralph Highnam, CEO

Volpara Health Technologies

[ralph.highnam@volparahealth.com](mailto:ralph.highnam@volparahealth.com)

t: +64 21 149 0541

Trevor Chappell

WE Communications

[WE-AUVolpara@we-worldwide.com](mailto:WE-AUVolpara@we-worldwide.com)

t: +61 407 933 437

### **About Volpara Health Technologies Limited (ASX: VHT)**

VHT is a health technology software company founded in 2009 on research originally conducted at Oxford University. VHT’s clinical functions for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide practice-management software helps with productivity, compliance, reimbursement, and patient tracking.

VHT’s technology and services have been used by customers and/or research projects in 39 countries and are supported by numerous patents, trademarks, and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$132 million, including A\$37 million in April/May 2020, and has made two significant acquisitions in MRS Systems, Inc. (patient tracking software), and CRA Health, LLC (risk and genetics software). VHT is based in Wellington, New Zealand.

For more information, visit [www.volparahealth.com](http://www.volparahealth.com).

### **About Natera, Inc. (NASDAQ: NTRA)**

Natera is a pioneer and global leader in cell-free DNA testing from a simple blood draw. The mission of the company is to change the management of disease worldwide with a focus on women's health, oncology, and organ health. Natera operates ISO 13485–certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers,

including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. For more information, visit [natera.com](https://natera.com).

For personal use only